Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
8MW2311 in Advanced Solid Tumors
NCT05416749Phase 2Suspended
- Sponsor
- Mabwell
- Start
- Aug 2022
- Primary completion
- Mar 2026
- Modality
- PEGylated Peptides, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of 8MW2311 in solid tumor, sponsored by Mabwell. Started Aug 2022; status: suspended.
02
Drugs
8MW2311
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05416749.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416749.